An international research team led by UK scientists has found clear evidence of a separate stage in tuberculosis (TB) infection where people have no symptoms but are more likely to go on and develop the full disease. The findings, published in Nature Medicine, suggest it may be possible to identify which people are most at risk of developing TB and can be treated in a more targeted way.
Professor Robert Wilkinson of the Francis Crick Institute and Imperial College London led a team including scientists from the University of Cape Town, South Africa, and the US National Institute of Health. He says: "We have shown clear evidence for a TB stage in-between latent infection and active disease. It could lead to a way of predicting which infected individuals will develop TB disease and transmit it on to others."
The results also offer hope in controlling the spread of disease. Robert says: "People ill with TB can infect up to 10-15 other people through close contact and if we can identify people in the transition stage before they transmit to other people, that's potentially a game-changer in terms of TB eradication."
Conventionally, TB infection is classed into two stages: 'latent' and 'active'. People with latent infection test positive for an immune response to the TB bacteria, Mycobacterium tuberculosis, but do not have the symptoms of active disease. Around 10% of people with latent TB infection progress to active disease if left untreated. However, currently there is no accurate way to predict which infected individuals will develop the disease.
It is estimated that there are 2 billion people around the world with latent TB infection. Active TB kills an estimated 1.5 million people annually - with people with HIV being at greater risk.
The researchers screened 265 HIV-positive people for TB infection in a township in Cape Town, South Africa where TB incidence is high. Of those who tested positive for latent TB, 35 were recruited to the study and were followed up over a period of six months.
The team used a combination of medical imaging techniques to study the lungs of the 35 patients - positron emission tomography (PET) and computed tomography (CT) scans - which highlighted areas of lung abnormalities as 'hot spots'.
Ten out of the 35 participants with latent TB infection had lung abnormalities consistent with a transitional or subclinical stage of TB progression. The other 25 participants had no hot spots and showed no signs of disease progression.
Over the course of the study, four of the 10 patients with lung abnormalities developed fully-fledged TB symptoms and started full treatment for TB. Two of these were found to have active TB confirmed by a standard sputum culture that tests for the presence of TB bacteriain the airways.
"We found evidence of differences in disease progression within a group of people that currently would all be diagnosed and managed as having the same latent TB infection, as none of them showed any outward symptoms of TB," Robert explains. "Those that had evidence of 'subclinical' disease on the PET/CT scans were at higher risk of developing the disease."
Imaging was continued during the treatment period for the four patients with active TB. This showed the lung abnormalities gradually diminishing over time. Robert says: "These high-tech images provide us with new ways to evaluate whether treatment has cured an infection. Most importantly, it will show whether we need to treat for the full recommended duration of six months, as most patients find the standard six months regimen of two or three different antibiotics very challenging."
Robert adds: "It would not be feasible to PET/CT scan everyone with latent TB as the majority of these people are in poor regions of sub-Saharan Africa and these particular scanners are expensive. Instead, the study is most promising in enabling other markers of this 'sub-clinical' stage of infection to be identified and be able to better predict those who will develop TB symptoms."
The research was supported by Wellcome, the Bill and Melinda Gates Foundation, the US National Institutes of Health, the National Research Foundation of South Africa, the Francis Crick Institute, the Medical Research Council of South Africa, and the European Union.
Notes to editors
* For a copy of the paper or further information, contact:
+44 (0)20 7611 2169
* Original paper: 'Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-d-glucose positron emission and computed tomography' by Hanif Esmail and colleagues will be published in Nature Medicine doi: 10.1038/nm.4161.
* The UK researchers want to acknowledge the support of senior colleagues at the Francis Crick Institute: Douglas Young and Anne O'Garra.
* The Francis Crick Institute is a new and distinctive biomedical research institute. Research groups are now moving into its purpose built laboratory in the King's Cross area of London. The institute's work - which is already underway at the Crick's Clare Hall, Lincoln's Inn Fields and Mill Hill laboratories - will help to understand why disease develops.
We will find new ways to diagnose, prevent and treat a range of illnesses − such as cancer, heart disease and stroke, infections and neurodegenerative diseases. We will bring together outstanding scientists from all disciplines, carrying out research that will help improve the health and quality of people's lives, and keeping the UK at the forefront of medical innovation. The Francis Crick Institute is a charity supported by the Medical Research Council, Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King's College.
* Wellcome exists to improve health for everyone by helping great ideas to thrive. We're a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate.
* Imperial College London is one of the world's leading universities. The College's 16,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for society.
Founded in 1907, Imperial builds on a distinguished past - having pioneered penicillin, holography and fibre optics - to shape the future. Imperial researchers work across disciplines to improve health and wellbeing, understand the natural world, engineer novel solutions and lead the data revolution. This blend of academic excellence and its real-world application feeds into Imperial's exceptional learning environment, where students participate in research to push the limits of their degrees.
Imperial collaborates widely to achieve greater impact. It works with the NHS to improve healthcare in west London, is a leading partner in research and education within the European Union, and is the UK's number one research collaborator with China.
Imperial has nine London campuses, including its White City
Campus: a research and innovation centre that is in its initial
stages of development in west London. At White City, researchers,
businesses and higher education partners will co-locate to create
value from ideas on a global scale.